Literature DB >> 9973158

Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years.

K Eberhardt1, E Fex.   

Abstract

OBJECTIVE: To investigate the clinical course in early rheumatoid arthritis (RA) patients followed prospectively, to relate course to outcome after 5 yr, and to try to identify prognostic features.
METHODS: A total of 183 patients with definite RA and a mean disease duration of 11 months were included. Of these, 75% were rheumatoid factor (RF) positive; 85% carried the shared epitope, 32% on both alleles. Most patients were assessed every 6 months. Disability was evaluated with the Health Assessment Questionnaire (HAQ) and radiographic findings according to Larsen. Remission was defined in two ways: with the American Rheumatism Association (ARA) criteria and as 'no arthritis at least at one follow-up visit'.
RESULTS: Twenty per cent achieved ARA-defined remission periods of at least 6 months duration; 21 were spontaneous and 18 drug induced. Average length of remission was 20.5 months. The remission periods constituted 7% of follow-up for all patients. Another 36% achieved remission according to the second definition. All 56% were considered to have a relapsing-remitting disease pattern, in contrast to the remaining 44% with a persistent disease pattern. More patients with persistent disease were treated with disease-modifying anti-rheumatic drugs (DMARDs) and had also received a larger number of different drugs. Outcome after 5 yr regarding disability, joint inflammation and joint damage was worse for patients with persistent disease. Neither ARA-defined remission nor disease pattern could be accurately predicted.
CONCLUSIONS: Long-term ARA-defined remission was rare, constituting 7% of follow-up for the entire cohort. For those 20% achieving remission, this period represented 34% of their follow-up. A total of 56% had a relapsing-remitting disease pattern and 44% had a persistent disease pattern. This classification had prognostic implications with persistency being a bad prognostic sign.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9973158     DOI: 10.1093/rheumatology/37.12.1324

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  22 in total

1.  Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: a prospective cohort study.

Authors:  A Stockman; B D Tait; R Wolfe; C A Brand; M J Rowley; M D Varney; R Buchbinder; K D Muirden
Journal:  Rheumatol Int       Date:  2005-09-07       Impact factor: 2.631

2.  Rheumatoid Arthritis: Early diagnosis and treatment outcomes.

Authors:  Behzad Heidari
Journal:  Caspian J Intern Med       Date:  2011

3.  The role of transforming growth factor β signaling in fibroblast-like synoviocytes from patients with oligoarticular juvenile idiopathic arthritis: dysregulation of transforming growth factor β signaling, including overexpression of bone morphogenetic protein 4, may lead to a chondrocyte phenotype and may contribute to bony hypertrophy.

Authors:  Annemarie C Brescia; Megan M Simonds; Suzanne M McCahan; Paul T Fawcett; Carlos D Rose
Journal:  Arthritis Rheumatol       Date:  2014-05       Impact factor: 10.995

4.  Radiological damage in patients with rheumatoid arthritis on sustained remission.

Authors:  G Cohen; L Gossec; M Dougados; A Cantagrel; P Goupille; J P Daures; N Rincheval; B Combe
Journal:  Ann Rheum Dis       Date:  2006-08-25       Impact factor: 19.103

Review 5.  An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.

Authors:  Nick J Bansback; Dean A Regier; Roberta Ara; Alan Brennan; Kamran Shojania; John M Esdaile; Aslam H Anis; Carlo A Marra
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Baseline HAQ and SF-36 questionnaire scores cannot predict clinical remission, radiographic progression or the need for biological therapy in a three-year prospective study of a Brazilian early rheumatoid arthritis cohort.

Authors:  Licia Maria Henrique da Mota; Leopoldo Luiz Dos Santos Neto; Ana Cristina V Oliveira; Ivânio Alves Pereira; Rufus W Burlingame; Henri A Ménard; Ieda Maria Magalhães Laurindo
Journal:  Rheumatol Int       Date:  2011-12-25       Impact factor: 2.631

7.  Tumour necrosis factor microsatellites and HLA-DRB1*, HLA-DQA1*, and HLA-DQB1* alleles in Peruvian patients with rheumatoid arthritis.

Authors:  F Castro; E Acevedo; E Ciusani; J A Angulo; F A Wollheim; M Sandberg-Wollheim
Journal:  Ann Rheum Dis       Date:  2001-08       Impact factor: 19.103

8.  Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.

Authors:  L Gossec; M Dougados; P Goupille; A Cantagrel; J Sibilia; O Meyer; J Sany; J-P Daurès; B Combe
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

9.  A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.

Authors:  S M M Verstappen; G A van Albada-Kuipers; J W J Bijlsma; A A M Blaauw; Y Schenk; H C M Haanen; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2004-05-06       Impact factor: 19.103

Review 10.  Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs.

Authors:  Tuulikki Sokka; Minja Envalds; Theodore Pincus
Journal:  Mod Rheumatol       Date:  2008-04-25       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.